Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2 results

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, Kharfan-Dabaja MA, Savani BN, Huang H, Kenderian S, Nagler A, Perales MA. Mohty M, et al. Leukemia. 2019 Dec;33(12):2767-2778. doi: 10.1038/s41375-019-0615-5. Epub 2019 Nov 5. Leukemia. 2019. PMID: 31690821 Review.
The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly e …
The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hemat …
Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma.
Hosen N. Hosen N. Cancers (Basel). 2019 Dec 15;11(12):2024. doi: 10.3390/cancers11122024. Cancers (Basel). 2019. PMID: 31847470 Free PMC article. Review.
CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B cell leukemia and lymphoma. ...We also reported that the activated integrin beta7 can serve as a specific target for CAR
CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B